Nanexa Secures €1.165 Billion Deal with Novo Nordisk to Drive Long‑Acting Drug‑Delivery Growth
Nanexa’s €1.165 bn deal with Novo Nordisk gives the Swedish nanotech firm its first major commercial partnership, positioning PharmaShell® to dominate the growing long‑acting injectable market.
3 minutes to read